ATE282412T1 - S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen - Google Patents
S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinenInfo
- Publication number
- ATE282412T1 ATE282412T1 AT02776528T AT02776528T ATE282412T1 AT E282412 T1 ATE282412 T1 AT E282412T1 AT 02776528 T AT02776528 T AT 02776528T AT 02776528 T AT02776528 T AT 02776528T AT E282412 T1 ATE282412 T1 AT E282412T1
- Authority
- AT
- Austria
- Prior art keywords
- omeprazole
- esomeprazole
- cyclodextrins
- inclusion complex
- cyclodextrin
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 3
- 229960000381 omeprazole Drugs 0.000 title abstract 2
- 229940097362 cyclodextrins Drugs 0.000 title 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 title 1
- 229960004770 esomeprazole Drugs 0.000 title 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- 239000011149 active material Substances 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- -1 benzimidazole compound Chemical class 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113792A GB2376231A (en) | 2001-06-06 | 2001-06-06 | Benzimidazole-cyclodextrin inclusion complex |
| PCT/GB2002/002542 WO2002098423A1 (en) | 2001-06-06 | 2002-06-06 | S-omeprazole (esomeprazole) inclusion complex with cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE282412T1 true ATE282412T1 (de) | 2004-12-15 |
Family
ID=9916040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02776528T ATE282412T1 (de) | 2001-06-06 | 2002-06-06 | S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040147481A1 (enExample) |
| EP (1) | EP1401442B1 (enExample) |
| JP (1) | JP2004536810A (enExample) |
| AT (1) | ATE282412T1 (enExample) |
| AU (1) | AU2002344386B2 (enExample) |
| CA (1) | CA2449769C (enExample) |
| DE (1) | DE60201995T2 (enExample) |
| ES (1) | ES2232780T3 (enExample) |
| GB (1) | GB2376231A (enExample) |
| LT (1) | LT5182B (enExample) |
| LV (1) | LV13154B (enExample) |
| NZ (1) | NZ529956A (enExample) |
| PL (1) | PL366940A1 (enExample) |
| PT (1) | PT1401442E (enExample) |
| RU (1) | RU2313343C2 (enExample) |
| WO (1) | WO2002098423A1 (enExample) |
| ZA (1) | ZA200309841B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1707217A1 (en) | 2004-12-17 | 2006-10-04 | Wacker Chemie AG | Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared |
| US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| SI1973896T1 (sl) * | 2005-12-28 | 2009-08-31 | Union Quimico Farma | Postopek priprave (S) - enantiomere omeprazola |
| KR20070069567A (ko) * | 2005-12-28 | 2007-07-03 | 에스케이케미칼주식회사 | 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법 |
| WO2009040825A1 (en) | 2007-09-25 | 2009-04-02 | Hetero Drugs Limited | A process for preparation of enantiomerically pure esomeprazole |
| WO2010097583A1 (en) * | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
| CN104277030B (zh) * | 2013-07-03 | 2016-04-20 | 湖南理工学院 | 一种反应萃取分离泮托拉唑对映体的方法 |
| CN103768028A (zh) * | 2014-01-15 | 2014-05-07 | 山东新时代药业有限公司 | 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3427787A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel |
| TW224049B (enExample) * | 1991-12-31 | 1994-05-21 | Sunkyong Ind Ltd | |
| US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| JPH0948730A (ja) * | 1995-06-02 | 1997-02-18 | Takeda Chem Ind Ltd | 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物 |
| AU5780696A (en) * | 1995-06-02 | 1996-12-18 | Takeda Chemical Industries Ltd. | Stabilized composition comprising an antiulcerative benzimid azole |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| JP4608031B2 (ja) * | 1997-03-13 | 2011-01-05 | ヘキサル アーゲー | アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化 |
| PT1018340E (pt) * | 1999-01-06 | 2003-12-31 | Tecnimede Sociedade Tecnico Medicinal Sa | Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem |
| KR100712039B1 (ko) * | 1999-08-26 | 2007-04-27 | 에이에이아이파머 인코포레이티드 | 알콕시로 치환된 벤즈이미다졸 화합물, 상기 화합물을포함하는 약학적 제제, 및 상기 화합물의 이용방법 |
| US6262085B1 (en) * | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| SE9903831D0 (sv) * | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
-
2001
- 2001-06-06 GB GB0113792A patent/GB2376231A/en not_active Withdrawn
-
2002
- 2002-06-06 AT AT02776528T patent/ATE282412T1/de not_active IP Right Cessation
- 2002-06-06 EP EP02776528A patent/EP1401442B1/en not_active Expired - Lifetime
- 2002-06-06 ES ES02776528T patent/ES2232780T3/es not_active Expired - Lifetime
- 2002-06-06 WO PCT/GB2002/002542 patent/WO2002098423A1/en not_active Ceased
- 2002-06-06 RU RU2003137221/15A patent/RU2313343C2/ru not_active IP Right Cessation
- 2002-06-06 AU AU2002344386A patent/AU2002344386B2/en not_active Ceased
- 2002-06-06 US US10/479,658 patent/US20040147481A1/en not_active Abandoned
- 2002-06-06 DE DE60201995T patent/DE60201995T2/de not_active Expired - Lifetime
- 2002-06-06 PL PL02366940A patent/PL366940A1/xx not_active Application Discontinuation
- 2002-06-06 NZ NZ529956A patent/NZ529956A/en unknown
- 2002-06-06 CA CA2449769A patent/CA2449769C/en not_active Expired - Fee Related
- 2002-06-06 PT PT02776528T patent/PT1401442E/pt unknown
- 2002-06-06 JP JP2003501462A patent/JP2004536810A/ja active Pending
-
2003
- 2003-12-03 LT LT2003100A patent/LT5182B/lt not_active IP Right Cessation
- 2003-12-19 ZA ZA200309841A patent/ZA200309841B/en unknown
-
2004
- 2004-01-06 LV LVP-04-01A patent/LV13154B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1401442A1 (en) | 2004-03-31 |
| JP2004536810A (ja) | 2004-12-09 |
| RU2003137221A (ru) | 2005-06-10 |
| CA2449769C (en) | 2010-12-14 |
| RU2313343C2 (ru) | 2007-12-27 |
| DE60201995T2 (de) | 2005-11-24 |
| ES2232780T3 (es) | 2005-06-01 |
| HK1064602A1 (en) | 2005-02-04 |
| PL366940A1 (en) | 2005-02-07 |
| LT2003100A (en) | 2004-09-27 |
| US20040147481A1 (en) | 2004-07-29 |
| ZA200309841B (en) | 2005-03-14 |
| LT5182B (lt) | 2004-12-27 |
| GB0113792D0 (en) | 2001-07-25 |
| AU2002344386B2 (en) | 2006-11-30 |
| PT1401442E (pt) | 2005-02-28 |
| GB2376231A (en) | 2002-12-11 |
| EP1401442B1 (en) | 2004-11-17 |
| CA2449769A1 (en) | 2002-12-12 |
| DE60201995D1 (de) | 2004-12-23 |
| WO2002098423A1 (en) | 2002-12-12 |
| LV13154B (en) | 2004-07-20 |
| NZ529956A (en) | 2005-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20040074L (no) | Fremgangsmåte for fremstilling av benzimidazoltype forbindelser | |
| AR033096A1 (es) | Acomposicion antifungal con aumentada biodisponibilidad | |
| ATE282412T1 (de) | S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen | |
| DK1475101T3 (da) | Antistof-holdige farmaceutiske opløsninger | |
| DK1784232T3 (da) | Biologisk aktive klæbeartikler og fremgangsmåder til fremstilling | |
| ECSP066662A (es) | Preparación farmacéutica que comprende un anticuerpo contra el receptor egf | |
| DE60200194D1 (de) | Freisetzungssystem von cyclopropenderivaten | |
| ECSP045104A (es) | Ligandos de los receptores de los cannabinoides | |
| DZ3402A1 (fr) | Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement | |
| ATE270903T1 (de) | Silberhaltige wundauflage | |
| AR033059A1 (es) | Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada. | |
| DE60228071D1 (de) | Spiropyrazol-verbindungen | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| CO5930056A1 (es) | Composiciones con ciclopopenos | |
| UY28897A1 (es) | Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb | |
| ITMI20022214A1 (it) | Procedimento per produrre una soluzione di cellulosa altamente omogenea. | |
| AR041639A1 (es) | Metodo para la sintesis de un compuesto de bencimidazol | |
| WO2004105201A3 (en) | Semiconductor nanocrystal-based optical devices and method of preparing such devices | |
| DK1200408T3 (da) | Vedhæftningsmiddel | |
| PE20070378A1 (es) | FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA | |
| NO20041671L (no) | Anthelmintic composition | |
| ATE269313T1 (de) | Tryptase-inhibitoren | |
| NO20026261L (no) | Etselosning | |
| DK1244614T3 (da) | Tryptase-inhibitorer | |
| CL2010000029A1 (es) | Método para limpiar equipos de elaboración de líquidos que contienen materias orgánicas que comprende poner el equipo en contacto con una solución de un compuesto de peryodado, en que dependiendo de si el valor de ph es inferior o superior a 6 se adiciona una solución de un valor de ph de 6 o superior, o un agente oxidante, respectivamente. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1401442 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |